Probiotix Health (FRA:X90) EBIT per Share: €-0.01 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Probiotix Health EBIT per Share?

Probiotix Health FRA:X90 EBIT per Share is €-0.01 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 1,173 Biotechnology companies, Probiotix Health ranks worse than 85251.41% on this metric.

Probiotix Health's EBIT per Share for the six months ended in Dec. 2025 was €-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Probiotix Health's EBIT per Share or its related term are showing as below:

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Probiotix Health was -14.50% per year. The lowest was -14.50% per year. And the median was -14.50% per year.

FRA:X90's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Probiotix Health's EBIT for the six months ended in Dec. 2025 was €-1.24 Mil.

Probiotix Health  (FRA:X90) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Probiotix Health EBIT per Share Related Terms

Probiotix Health EBIT per Share Historical Data

* Premium members only.

The historical data trend for Probiotix Health's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Probiotix Health EBIT per Share Chart

Probiotix Health Annual Data
Trend Dec18 Dec19 Dec20 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial 0.00 0.00 -0.01 -0.01 -0.01

Probiotix Health Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.01 -0.00 -0.01

Probiotix Health EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Probiotix Health's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.415/172.917
=-0.01

Probiotix Health's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.24/187.667
=-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of €-0.01 mean?
Probiotix Health (FRA:X90) has a EBIT per Share of €-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Probiotix Health and its competitors. According to the industry distribution chart, Probiotix Health ranks #999999 out of 1173 companies in the Biotechnology industry.
Is Probiotix Health's EBIT per Share too high?
Probiotix Health's current EBIT per Share is €-0.01. Based on the distribution chart, Probiotix Health ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Probiotix Health's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Probiotix Health ranks #999999 out of 1173 companies for EBIT per Share. This places Probiotix Health in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Probiotix Health and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Probiotix Health's current EBIT per Share is €-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Probiotix Health (FRA:X90) has a current EBIT per Share of €-0.01. The stock's GF Value™ is €0.09, compared to a current price of €0.07 — trading 22.8% below its estimated fair value. The current EBIT per Share is €-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Probiotix Health (FRA:X90), the current EBIT per Share is €-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Probiotix Health Business Description

Other Exchanges PBX:UK
Address Nostell Business Estate, First Floor Zucchi Suite, Wakefield, GBR, WF4 1AB
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.